CS
RLMD icon

Credit Suisse’s Relmada Therapeutics RLMD Stock Holding History

Credit Suisse’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$3 – 3637
2022
Q4 		$3 Sell
1
-16,679
-100% -$146K ﹤0.01% 3872
2022
Q3 		$617K Sell
16,680
-1,242
-7% -$34.4K ﹤0.01% 2665
2022
Q2 		$340K Buy
17,922
+226
+1% +$4.93K ﹤0.01% 3092
2022
Q1 		$478K Buy
17,696
+6,789
+62% +$140K ﹤0.01% 3010
2021
Q4 		$246K Buy
+10,907
New +$243K ﹤0.01% 4202
2021
Q3 		– Sell
-7,223
Closed -$231K – 4518
2021
Q2 		$231K Buy
7,223
+19
+0.3% +$660 ﹤0.01% 4225
2021
Q1 		$254K Sell
7,204
-4,771
-40% -$167K ﹤0.01% 4050
2020
Q4 		$383K Buy
11,975
+6,012
+101% +$207K ﹤0.01% 3900
2020
Q3 		$224K Sell
5,963
-1,984
-25% -$76.7K ﹤0.01% 3795
2020
Q2 		$355K Buy
+7,947
New +$336K ﹤0.01% 3494

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's RLMD Position: Q1 2023 in Review

Credit Suisse sold out of Relmada Therapeutics (RLMD) in Q1 2023, closing a stake of 1 share — an estimated $3 sold.

Credit Suisse first reported a position in RLMD in Q2 2020 and held it in 10 quarters. The position peaked at $617K in Q3 2022. 91 funds tracked by Wall St. Rank hold RLMD as of Q1 2023.

  • Credit Suisse reported no remaining Relmada Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 1 Relmada Therapeutics share in Q1 2023, an estimated $3.
  • Credit Suisse first reported a position in Relmada Therapeutics in Q2 2020 and held it in 10 quarters.
  • Credit Suisse's Relmada Therapeutics position peaked at $617K in Q3 2022.
  • 91 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.